Erasca Surges on Positive Phase 1 Trial Results for Cancer Treatment

Erasca (NASDAQ:ERAS) shares rose by 8.94% following encouraging phase 1 clinical trial results of its treatment candidate, ERAS-0015, which showed a significant reduction in pancreatic tumors and favorable safety data. Jefferies raised its price target for the stock to $24 from $21.

By Angelica Ballesteros Wed, July 15, 2026 at 2:40 AM GMT+3 3 min read · Yahoo Finance · July 14, 2026, 23:40 UTC

Erasca Surges on Positive Phase 1 Trial Results for Cancer Treatment

Tickers: $ERAS

Topics: biotech cancer pharmaceuticals stock_movement

Read the full article at Yahoo Finance

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC